John M Kirkwood, MD
Session Chair
Financial Disclosure
nkyra Therapeutics, Atarazis AI Inc., Axio Research LLC, Boxer Capital,Bristol Myers Squibb, Daiichi Sankyo Inc., Engage Health Media, GEHealthcare Inc., Intellisphere LLC, IQVIA, Merck, Natera Inc., NovartisPharmaceuticals, OncoCyte Corporation, Regeneron PharmaceuticalsInc., Replimune Inc., Scitaris GmbH & Co. KG, Sun PharmaceuticalsIndustries, Syntaxx Communications, Takeda, Zola TherapeuticsResearch Trial Support to Institution:Amgen Inc., Ankyra Therapeutics, Bristol Myers Squibb, CheckmatePharmaceuticals, Harbour BioMed, Immunocore Ltd., Immvira PharmaCo., Iovance Biotherapeutics, Lion Biotechnologies Inc., Lytix BiopharmaAS, Merck, Novartis Pharmaceuticals, Regeneron Pharmaceuticals Inc.,Takeda, Verastem Inc.
Consultant
Amgen Inc., Ankyra Therapeutics, Bristol Myers Squibb, CheckmatePharmaceuticals, Harbour BioMed, Immunocore Ltd., Immvira PharmaCo., Iovance Biotherapeutics, Lion Biotechnologies Inc., Lytix BiopharmaAS, Merck, Novartis Pharmaceuticals, Regeneron Pharmaceuticals Inc.,Takeda, Verastem Inc.
Researcher